Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Sangamo Therapeutics (SGMO) Income from Non-Controlling Interests (2018 - 2021)

Sangamo Therapeutics (SGMO) has disclosed Income from Non-Controlling Interests for 4 consecutive years, with -$5000.0 as the latest value for Q2 2021.

  • For Q2 2021, Income from Non-Controlling Interests rose 86.11% year-over-year to -$5000.0; the TTM value through Mar 2022 reached -$5000.0, up 92.96%, while the annual FY2021 figure was -$11000.0, 91.27% up from the prior year.
  • Income from Non-Controlling Interests hit -$5000.0 in Q2 2021 for Sangamo Therapeutics, up from -$6000.0 in the prior quarter.
  • Across five years, Income from Non-Controlling Interests topped out at $42000.0 in Q3 2020 and bottomed at -$555000.0 in Q4 2018.
  • Average Income from Non-Controlling Interests over 4 years is -$84090.9, with a median of -$54000.0 recorded in 2019.
  • On a YoY basis, Income from Non-Controlling Interests climbed as much as 177.78% in 2020 and fell as far as 31.48% in 2020.
  • Sangamo Therapeutics' Income from Non-Controlling Interests stood at -$555000.0 in 2018, then soared by 90.27% to -$54000.0 in 2019, then plummeted by 31.48% to -$71000.0 in 2020, then skyrocketed by 92.96% to -$5000.0 in 2021.
  • According to Business Quant data, Income from Non-Controlling Interests over the past three periods came in at -$5000.0, -$6000.0, and -$71000.0 for Q2 2021, Q1 2021, and Q4 2020 respectively.